Piet Wigerinck
Director/Board Member bei IPSEN
Vermögen: 81 004 $ am 31.03.2024
Profil
Derzeit ist Piet Wigerinck Chief Scientific Officer von Galapagos NV. Er ist auch im Vorstand von Ipsen SA und Ipsen Pharma SAS. In der Vergangenheit war er Vice President-Drug Discovery & Early Development bei Tibotec Pharmaceuticals und Vice President von Drug Discovery & Development Solutions Ltd. Dr. Wigerinck erhielt einen Doktortitel von der Katholieke Universiteit Leuven.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
IPSEN SA
0,00% | 31.12.2022 | 680 ( 0,00% ) | 81 004 $ | 31.03.2024 |
Aktive Positionen von Piet Wigerinck
| Unternehmen | Position | Beginn |
|---|---|---|
| IPSEN | Director/Board Member | 01.05.2018 |
University Hospital Antwerp
 University Hospital Antwerp Hospital/Nursing ManagementHealth Services University Hospital Antwerp provides clinical, patient care, academic training and scientific research services. The company was is headquartered in Belgium. | Director/Board Member | - |
miDIAGNOSTICS NV
 miDIAGNOSTICS NV Miscellaneous Commercial ServicesCommercial Services miDIAGNOSTICS NV develops a computer chip powered portable medical laboratory. The company is headquartered in Leuven, Belgium. | Director/Board Member | - |
Atriva Therapeutics GmbH
 Atriva Therapeutics GmbH BiotechnologyHealth Technology Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany. | Director/Board Member | - |
| UZA Foundation | Director/Board Member | - |
Ehemalige bekannte Positionen von Piet Wigerinck
| Unternehmen | Position | Ende |
|---|---|---|
| GALAPAGOS NV | Chief Tech/Sci/R&D Officer | 31.12.2021 |
Xinvento BV
 Xinvento BV BiotechnologyHealth Technology Part of Rhythm Pharmaceuticals, Inc., Xinvento BV is a Dutch biotech company that develops therapies for congenital hyperinsulinism. The private company is based in Amsterdam, Netherlands. The company was founded in 2021 by Claudine van der Sande, Sarah Hafith-de Boer, Piet Wigerinck. Claudine van der Sande has been the CEO since 2021. Xinvento was acquired by Rhythm Pharmaceuticals Netherlands BV on February 27, 2023 for $222.43 million. | Founder | - |
| Tibotec-Virco Comm Va | Corporate Officer/Principal | - |
Drug Discovery & Development Solutions Ltd.
 Drug Discovery & Development Solutions Ltd. Miscellaneous Commercial ServicesCommercial Services Drug Discovery & Development Solutions Ltd. engages in the provision of financial services. The company is headquartered in Singapore. | Corporate Officer/Principal | - |
Ausbildung von Piet Wigerinck
| Katholieke Universiteit Leuven | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| IPSEN | Health Technology |
| GALAPAGOS NV | Health Technology |
| Private Unternehmen | 7 |
|---|---|
University Hospital Antwerp
University Hospital Antwerp Hospital/Nursing ManagementHealth Services University Hospital Antwerp provides clinical, patient care, academic training and scientific research services. The company was is headquartered in Belgium. | Health Services |
miDIAGNOSTICS NV
miDIAGNOSTICS NV Miscellaneous Commercial ServicesCommercial Services miDIAGNOSTICS NV develops a computer chip powered portable medical laboratory. The company is headquartered in Leuven, Belgium. | Commercial Services |
Drug Discovery & Development Solutions Ltd.
Drug Discovery & Development Solutions Ltd. Miscellaneous Commercial ServicesCommercial Services Drug Discovery & Development Solutions Ltd. engages in the provision of financial services. The company is headquartered in Singapore. | Commercial Services |
Atriva Therapeutics GmbH
Atriva Therapeutics GmbH BiotechnologyHealth Technology Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany. | Health Technology |
| Tibotec-Virco Comm Va | |
Xinvento BV
Xinvento BV BiotechnologyHealth Technology Part of Rhythm Pharmaceuticals, Inc., Xinvento BV is a Dutch biotech company that develops therapies for congenital hyperinsulinism. The private company is based in Amsterdam, Netherlands. The company was founded in 2021 by Claudine van der Sande, Sarah Hafith-de Boer, Piet Wigerinck. Claudine van der Sande has been the CEO since 2021. Xinvento was acquired by Rhythm Pharmaceuticals Netherlands BV on February 27, 2023 for $222.43 million. | Health Technology |
| UZA Foundation |
